Post by NBE-Therapeutics AG

Shaping the future of oncology together! Both scientists as well as the management of NBE Therapeutics participated at the Swiss Biotech Day 2026 alongside T3 Pharmaceuticals AG and Boehringer Ingelheim. While we were actively participating at the scientific part with a panel discussion on Antibody-Drug Conjugates led by our CSO Carl Deutsch, PhD, MBA, the other focus of our activities were strengthening existing as well as building new partnerships with collaborating partner companies. Read the full article here: https://lnkd.in/d2qfcntC